Centerra Gold: Why I Am Raising My Price Target

Centerra Gold is reiterated as a Strong Buy with the analyst price target raised from $24.30 to $28 per share. Öksüt’s 2026 production guidance increased to 120K–135K ounces with no higher AISC range, supporting higher valuation in the SOTP framework. Mount Milligan is valued at ~$2.14B, Öksüt at ~$1.05B, and Thompson Creek at ~$850M, while Goldfield and Kemess remain meaningfully discounted.

Analysis

This matters less as a one-day analyst-call and more as a signal that the market may be underpricing asset mix optionality: incremental ounces coming through without a commensurate cost reset should narrow the discount versus peers that are still being valued as a static gold beta. The near-term winner is CGAU; the second-order winner is any mid-cap producer with a credible internal growth pipeline and low visible capex, because investors will start paying more for embedded production growth than for headline reserve size alone.

The risk is that the rerating only holds if the next operating print confirms the ramp and the cost curve does not reaccelerate. Over 1-3 months, the key catalyst is whether updated guidance actually translates into higher quarterly revisions and stronger free cash flow; over 6-18 months, the real test is whether management can prove these assets deserve SOTP treatment rather than a holding-company discount. If gold weakens materially, the multiple expansion thesis can stall even if ounces rise.

Contrarian take: the market may already be assigning some value to these assets, and the remaining upside depends on execution quality, not just higher target prices. Any miss at Mount Milligan or cost drift at Öksüt would likely compress the multiple quickly, because the thesis is built on “more ounces, same AISC,” which is easy to say and harder to deliver. The clean falsifier is a 2026 guidance cut or an AISC reset in the next operating update.

Key Decisions for Investors

• Long CGAU on pullbacks over the next 1-3 weeks ahead of the next operating update; thesis is a rerating from guidance credibility, not just gold beta. Upside/downside is roughly 2:1 if the company confirms volume growth without cost inflation.
• If you want to neutralize gold beta, pair long CGAU / short GDX for 1-3 months. That isolates idiosyncratic rerating; thesis breaks if gold spikes sharply or if CGAU fails to deliver the higher production path.
• Buy CGAU call spreads in the 3-6 month tenor only if liquidity is acceptable; this is a catalyst trade on estimate revisions, not a long-dated structural call. Use a hard exit if 2026 guidance is not reiterated.
• Avoid chasing the move if CGAU trades to the implied SOTP gap quickly; the stock is most vulnerable to a give-back on any cost or throughput miss, so scale in rather than full-size immediately.